Cadrenal Therapeutics Press Release
PONTE VEDRA, Fla., Nov. 12, 2024 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant,...
Cadrenal Therapeutics Press Release
PONTE VEDRA, Fla., Nov. 12, 2024 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant,...
Cadrenal Therapeutics Press...